Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to dissemintate knowledge & skills of Acute Cardiovascular Care
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission: To promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our goal is to reduce the burden in cardiovascular disease in Europe through percutaneous cardiovascular interventions.
Our Mission is "to improve the quality of life of the population by reducing the impact of cardiac rhythm disturbances and reduce sudden cardiac death"
To improve quality of life and logevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
Working Groups goals is to stimulate and disseminate scientific knowledge in different fields of cardiology.
ESC Councils goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
Dr. Sabine Pankuweit,
The first part of the ‘pro and contra’ session addressed the question whether viral persistence is clinically and prognostic relevant.
In the first part (pro) presented by Prof. Schultheiss (Berlin, Germany), data with regard to prevalence of cardiotropic viruses associated with mycarditis and dilated cardiomypathy were discussed. It was shown that not only CVB3 and adenoviral persistence are negative prognostic factors in those patients, but in addition PVB 19 in a substantial amount of patients. As the pathogenetic role of PVB 19 in heart muscle diseases so far is not completely understood and under discussion, Prof. Schultheiss was able to show that viral load alone is not important, but transcriptional activity of this virus makes the difference. He proposes first, that infection of endothelial cells with PVB 19 occurs in the bone marrow. Secondly, genetic predisposition in a given patient is responsible for the type of the immune response, which includes adequate activation of regulatory factors such as reg T-cells or micro RNA’s.
In the contra part given by Prof. Heymans (Maastricht, Netherlands) the speaker points out that the prognostic relevance of viral persistence in myocardial diseases is not a question with regard to the virus but depends on the degree of heart failure, as the failing heart is more prone for viral reactivation. Secondly, he was able to show that for example PVB 19 is present not only in patients with mycarditis and DCM, but in addition in other forms of heart disease and in normal hearts with low copy numbers. He reported, that the immunogenetic background is responsible in patients with acute mycarditis and not the virus per se and that the evolvement of DCM after viral infection is unclear as clinical evidence, for that hypothesis is lacking.
In the rebuttal Prof. Schultheiss points out, that:
Prof. Heymans points out, that so far the percentage of patients with active replication of PVB 19 is not known and that on the other hand IvIg therapy in PVB 19 related DCM improves cardiac function. He concluded that the failing heart is an immune diseased heart.
Both speakers summarized that gene factors, status of the immune system, viral positivity and activity in addition to structural and metabolic features in a given patient are responsible for the extend of heart failure. The second part of the ‘pro and contra’ session addressed the question whether endomyocardial biopsy is the diagnostic gold standard.
In the first part (pro), Prof. Cooper (Rochester, USA) pointed out that in all cases where EMB is performed, a clinical usefull, prognostic and therapeutic relevant information should be the aim, keeping the costs and the safety of the patient in mind. As it is known that especially in giant cell, myocarditis and some forms of granulomatous myocardial diseases outcome is poor, EMB can add data which are relevant for the treatment and outcome for the patients. As it was shown recently, that myocardial inflammation detected by immunohistochemistry has a poor outcome, too, EMB is helpful on those cases, where myocardial inflammation to a higher extend is suspected.
In the rebuttal Prof. Schulz-Menger (Berlin, Germany) informed that cardiac MRI after defining different criteria for the diagnosis of myocardial inflammatory diseases is able to detect inflammation with high sensitivity and specificity, thus helping to differentiate forms of myocardial inflammation, oedema and fibrosis and is therefore able to provide prognostic relevant information for the patients.
Both speakers summarized, that 1) in addition to clinical scenarios defined EMB is of special importance in giant cell and fulminant myocarditis, in granulomatous myocarditis and viral induced forms, and patients after therapy should be followed in registries. MRI as non-invasive tool with regard to the diagnosis of mycarditis is sensitive, and is also helpful to follow patients after biopsy and treatment, and may be used to diagnose patients with normal ejection fraction. EMB and MRI are not exclusive of one another but should used in combination to provide as much information as needed, to reach a definitive diagnosis in a given patient.
Controversies in myocarditis
© 2016 European Society of Cardiology. All rights reserved